Xolair 150 MG/ML syringeml
Ended Awarded
- Contract number
- SPE2DB26FYM43
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $61,896
Award facts
- Contract value 100% obligated
- $61,896.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $61,896 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 150 mg/ml syringes. The delivery order, issued on October 28, 2025, is scheduled for completion by November 19, 2025, and carries no set-aside designation, indicating the vendor competed in unrestricted federal procurement. DMS Pharmaceutical Group, registered in the System for Award Management since 2001, specializes in distributing branded and generic pharmaceuticals, biologics, vaccines, and medical consumables to federal agencies, particularly the Department of Defense.
This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy. The underlying IDC, valued at $499,999,999 with a completion date of December 31, 2036, authorizes the issuance of firm fixed-price delivery orders for comprehensive pharmaceutical and medical supply needs across Department of Defense healthcare facilities worldwide. The current award for Xolair, a biologic immunosuppressant used in treating severe asthma and chronic idiopathic urticaria, reflects DMS Pharmaceutical Group's demonstrated capability to fulfill specialized pharmaceutical requirements within the federal military medical supply chain.
Quick answers
Who was awarded contract SPE2DB26FYM43?
SPE2DB26FYM43 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 28, 2025.
How much is contract SPE2DB26FYM43 worth?
The government has obligated $61,896 on SPE2DB26FYM43.
Is contract SPE2DB26FYM43 an order under another contract?
Yes. SPE2DB26FYM43 is a delivery order under SPE2DB22D9316, an indefinite delivery contract.
Was contract SPE2DB26FYM43 competed?
The extent of competition for SPE2DB26FYM43 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award